ReviewEndocrine connections2018
The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders.
Review in Endocrine connections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD).Clinical endocrinology · 2025Pooled it
- Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective.Hormone research in paediatrics · 2019Guideline
- Pharmacokinetic and pharmacodynamic results from a randomized controlled study with the growth hormone secretagogue receptor blocker PF-5190457 in recently abstinent patients with alcohol use disorder.The international journal of neuropsychopharmacology · 2026Trial
- Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH.The Journal of clinical endocrinology and metabolism · 2023Trial
- Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3.The Journal of clinical endocrinology and metabolism · 2023Trial
- Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.The Journal of clinical endocrinology and metabolism · 2022Trial
- Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.mAbs · 2026Article
- METTL18 is Required for Developmental, Metabolic, and Endocrine Regulation of Mammalian Growth.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Precision Dosing for Pediatric Growth Hormone Deficiency With Daily and Weekly Growth Hormone.MedComm · 2026Article
- Functional Characterization of Tret1-like Gene and Its Critical Role in Regulating Growth inInternational journal of molecular sciences · 2026Article
- Model-based somapacitan dosing and IGF-I response in children born SGA or with ISS, Noonan or Turner syndromes.Journal of the Endocrine Society · 2026Article
- Association between recombinant human growth hormone therapy and refractive status in Korean children with idiopathic short stature: a cross-sectional study.Scientific reports · 2026Article
- Identification of Potential Roles of Bestrophin 3 in the Growth Performance of Ortiental River PrawnInternational journal of molecular sciences · 2026Article
- Unraveling the Genetic Heterogeneity of Isolated Growth Hormone Deficiency: Insights from the GENHYPOPIT Cohort.Hormone research in paediatrics · 2026Article
- Harmonization of IGF1 immunoassays towards a higher-order LC-MS/MS reference anchor.Endocrine connections · 2026Article
- Growth Retardation in an Adolescent Secondary to Cushing's Disease Caused by a Pituitary Microadenoma: A Case Report.Reports (MDPI) · 2026Article
- Systems biology insights into the molecular drivers of childhood stunting and implications for intervention.Frontiers in nutrition · 2026Review
- Treatment with long-acting growth hormone: effectiveness and safety.Frontiers in endocrinology · 2026Review
- Seven-year Safety and Efficacy of Somapacitan in Children With GH Deficiency: Final Results From REAL 3.Journal of the Endocrine Society · 2026Article
- Human Cancers Derived from Either Genetic or Lifestyle Factors Are Initiated by Impaired Estrogen Signaling.Cancers · 2025Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growth hormone (GH)-insulin-like growth factor (IGF)-I axis is a key endocrine mechanism regulating linear growth in children. While paediatricians have a good knowledge of GH secretion and assessment, understanding and use of measurements of the components of the IGF system are less current in clinical practice. The physiological function of this axis is to increase the anabolic cellular processes of protein synthesis and mitosis, and reduction of apoptosis, with each being regulated in the appropriate target tissue. Measurement of serum IGF-I and IGF-binding protein (IGFBP)-3 concentrations can complement assessment of GH status in the investigation of short stature and contribute to prediction of growth response during GH therapy. IGF-I monitoring during GH therapy also informs the clinician about adherence and provides a safety reference to avoid over-dosing during long-term management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.